WuXi AppTec Co. Ltd. executed a share repurchase program worth HK$1.26 billion ($160 million) over 10 consecutive days starting May 26, yet its stock price continued to decline. The sell-off accelerated on June 8 after the U.S. Department of Defense added the pharmaceutical services provider to a list of Chinese military companies. Despite the buyback campaign, which totaled 9.94 million shares, the company faces significant geopolitical risks that threaten its primary revenue stream.

Buyback details and market reaction

From May 26 to June 8, WuXi AppTec actively repurchased shares in an effort to bolster investor confidence. On June 8 alone, the company bought back 912,600 shares at prices between HK$119.20 and HK$123.80 per share, spending HK$110 million. The company stated that these repurchased shares will be held as treasury stock for use in its incentive scheme for senior and technical staff, meaning the number of outstanding shares remains unchanged and per-share earnings are not immediately enhanced.

Financial performance and exposure

WuXi AppTec's financial results for 2025 indicate a heavy reliance on the U.S. market. Revenue from U.S. customers increased 34.3% to 31.25 billion yuan ($4.61 billion), representing nearly 70% of its total turnover of 45.46 billion yuan. The company reported an order backlog exceeding 59.7 billion yuan at the end of the first quarter, a year-on-year rise of 23.6%. Despite these operational metrics, the stock trades at a price-to-earnings ratio of approximately 15 times, lower than the 23 times ratio of its peer, WuXi Biologics.

Geopolitical risks and industry context

The U.S. designation poses a threat primarily through compliance reviews within the supply chains of clients funded by federal agencies like the National Institutes of Health (NIH), rather than through direct sanctions. WuXi AppTec has firmly denied any military affiliation, stating it does not provide services to the Chinese military. This buyback trend is mirrored across the sector, with about 80 pharmaceutical and biotech companies conducting repurchases this year. Other WuXi group entities, such as WuXi Biologics and WuXi XDC, announced buyback plans of up to $400 million and $100 million, respectively, funded by cash on hand.